- Pet cancer therapeutics, including chemotherapy, targeted therapy, immunotherapy, and others, are becoming essential in veterinary oncology due to the rising incidence of cancer in companion animals and growing awareness among pet owners regarding advanced treatment options
- The increasing demand for pet cancer therapeutics is largely driven by the growing pet population, rising healthcare spending on pets, and technological advancements in veterinary diagnostics and treatments
- North America dominated the pet cancer therapeutics market with the largest revenue share of 41.6% in 2024, fueled by early adoption of advanced veterinary care, high pet ownership rates, and robust healthcare infrastructure for companion animals. The U.S. contributes significantly to this growth through extensive investments in animal health research and the presence of major market players focused on oncology solutions
- Asia-Pacific is projected to be the fastest-growing region in the pet cancer therapeutics market during the forecast period, with a CAGR of 11.3% from 2025 to 2032, driven by rapid urbanization, increasing disposable incomes, and growing awareness about veterinary oncology care in countries such as China, India, and Japan
- The chemotherapy segment dominated the pet cancer therapeutics market with the largest revenue share of 38.4% in 2024, owing to its widespread use in treating a variety of pet cancers
